Gu Meizhen, Guan Jian, Zhao Limin, Ni Kun, Li Xiaoyan, Han Zhao
Department of Otolaryngology, Shanghai Children's Hospital, Shanghai Jiao Tong University, Shanghai 200040, China.
Int J Clin Exp Pathol. 2013 May 15;6(6):1132-7. Print 2013.
To investigate the expression of extracellular matrix protein 1 (ECM1) in benign laryngeal lesions, precancerous lesions and malignant laryngeal lesions and analyze the clinical significance of ECM1 changes in the pathogenesis and metastasis of laryngeal carcinoma.
A total of 46 patients with laryngeal lesions were recruited with a median age of 48.2 years (range: 33-67 years). Among these patients, 29 had laryngeal carcinoma (12 with metastasis and 17 without metastasis), 8 had benign laryngeal lesions and 9 had precancerous laryngeal lesions (laryngeal leukoplakia). Immunofluorescence staining was employed to detect the protein expression of ECM1 in benign laryngeal lesions, laryngeal leukoplakia and malignant laryngeal lesions; RT-PCR was used to measure the mRNA expression of ECM1 in laryngeal carcinoma and benign laryngeal lesions.
ECM1 expression was detected in 25% (2/8) of patients with benign laryngeal lesions, 78% (7/9) of patients with precancerous laryngeal lesions, and 100% (29/29) of patients with laryngeal carcinoma. Among the laryngeal carcinoma patients, high ECM1 expression (+++) was found in 64.7% (11/17) of patients without lymph node metastasis and 91.7% (11/12) of patients with lymph node metastasis. Increased ECM1 expression was found in laryngeal carcinoma when compared with other laryngeal lesions and the ECM1 expression in patients with metastasis was significantly higher than that patients without metastasis (P<0.01). RT-PCR showed that the mRNA expression of ECM-1 in laryngeal carcinoma was markedly higher than that in benign laryngeal lesions.
ECM1 expression is in an increasing order in benign laryngeal lesions, precancerous laryngeal lesions and malignant laryngeal lesions. Meanwhile, the metastatic laryngeal carcinoma has higher ECM1 expression than laryngeal carcinoma without metastasis. Our findings suggest that ECM1 plays promotive roles in the occurrence, development and metastasis of laryngeal carcinoma.
探讨细胞外基质蛋白1（ECM1）在喉良性病变、癌前病变及喉恶性病变中的表达情况，并分析ECM1变化在喉癌发生发展及转移中的临床意义。
共纳入46例喉病变患者，中位年龄48.2岁（范围：33 - 67岁）。其中，喉癌患者29例（12例有转移，17例无转移），喉良性病变患者8例，喉癌前病变（喉白斑）患者9例。采用免疫荧光染色检测ECM1在喉良性病变、喉白斑及喉恶性病变中的蛋白表达；采用逆转录聚合酶链反应（RT-PCR）检测喉癌及喉良性病变中ECM1的mRNA表达。
喉良性病变患者中25%（2/8）检测到ECM1表达，喉癌前病变患者中78%（7/9）检测到ECM1表达，喉癌患者中100%（29/29）检测到ECM1表达。在喉癌患者中，无淋巴结转移患者的ECM1高表达（+++）率为64.7%（11/17），有淋巴结转移患者的ECM1高表达（+++）率为91.7%（11/12）。与其他喉病变相比，喉癌中ECM1表达增加，且有转移患者的ECM1表达明显高于无转移患者（P<0.01）。RT-PCR结果显示，喉癌中ECM-1的mRNA表达明显高于喉良性病变。
ECM1表达在喉良性病变、喉癌前病变及喉恶性病变中呈递增趋势。同时，有转移的喉癌比无转移的喉癌ECM1表达更高。我们的研究结果表明，ECM1在喉癌的发生、发展及转移中起促进作用。
